EDGAR·FLOW

bioAffinity Technologies, Inc. — Form S-1

Filed November 20, 2026 · analyzed by the Registration Agent
S-1 — Neutral significance 28/100
What the filing says
bioAffinity Technologies filed an S-1 registration statement on November 20, 2026, to permit selling stockholders to resell up to 999,673 shares of common stock, comprised of 980,072 shares issuable from Series C warrants (exercise price $6.122/share) held by Armistice Capital Master Fund Ltd., and 19,601 shares from Placement Agent Warrants (also $6.122/share). The company receives no proceeds from share sales but may receive ~$6.1 million if all warrants are exercised for cash. No company capital is raised by this registration.
Why this rating

Warrant-exercise registration is routine for small-cap biotech. While potential $6.1M inflow is 27% of $22.6M market cap, receipt is contingent and optional. No immediate capital or strategic change occurs.

View original filing on SEC.gov ↗ BIAFW · stock on Yahoo Finance ↗

See more from November 20, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.